Semaglutide stock in the UK: how supply works and what it means for you

Why semaglutide stock in the UK has been patchy — and how it's changed

When Wegovy launched in the UK in late 2023, global demand outstripped Novo Nordisk's production capacity almost immediately. The situation was made worse because semaglutide was already being prescribed under its diabetes brand — creating a supply chain pulled in two directions. The MHRA worked with Novo Nordisk to prioritise supply to the UK market, and by 2025 the picture had improved considerably, though not evenly.

The pattern that emerged was predictable: starter doses (0.25mg) tended to be in stock more reliably than the upper maintenance doses, because fewer patients reach those levels and because manufacturers prioritised the doses needed for the highest number of new starters. Higher doses like 1.7mg and 2.4mg saw more disruption. If you're wondering whether to start treatment while supply is uncertain, that context is worth knowing: beginning is usually more straightforward than maintaining a higher dose.

A question our prescribers hear most weeks is whether it's safe to switch pharmacy mid-treatment if your usual one runs out of a dose. Clinically, the answer is that it's possible, but it needs a prescriber's involvement, you'd need confirmation that the new pharmacy can see your dose history, and that any supply gap is managed correctly rather than simply skipped. The process of getting semaglutide from a new provider involves a full clinical re-review, which is the right approach even if it feels like an inconvenience.

What 'in stock' actually means, and the counterfeit risk hiding underneath the shortage

One predictable consequence of genuine shortages is that illegitimate sellers move in. When patients can't easily find semaglutide through registered pharmacies, some are tempted by social-media sellers or websites offering it cheaply and without a prescription. The MHRA has made large seizures of fake weight-loss pens (some containing dangerous substances) and continues to warn the public about this risk. The only way to know a product is genuine is to obtain it from a pharmacy you can verify on the GPhC register.

A seller advertising these medicines without a clinical assessment is a red flag, full stop. So is a price that sits far below the typical private market. For context on what legitimate treatment realistically costs, a breakdown of UK Wegovy pricing can help you recognise when something looks too good to be true.

It's also worth being clear about a category of products sometimes marketed as "peptides" or research compounds. These are not licensed medicines, are not assessed for safety or purity, and have no place in a legitimate treatment plan. Understanding what peptide semaglutide actually is and why it differs from licensed Wegovy matters if you've seen that terminology in your searches.

How to find genuine semaglutide supply, and what the NHS route actually offers

The NHS does make semaglutide available, but access is tightly controlled. Under NICE guidance (TA875), it's recommended only within specialist weight management services, for a maximum of two years, for adults with a BMI of 35 or above plus at least one weight-related condition. Waiting lists for those services are frequently long. For many people, a regulated private pharmacy is the faster, equally safe alternative, provided the clinical rigour is genuinely in place.

More detail on what NHS eligibility looks like and how it compares to the private route is covered on the NHS semaglutide page. If you're trying to work out whether you'd qualify for treatment through any route, understanding who Wegovy is licensed for in the UK is a good starting point.

Stock availability through private pharmacies varies by dose and by week. A GPhC-registered pharmacy with Novo Nordisk supply relationships is best placed to confirm what's available at the dose relevant to your treatment stage. For a broader look at what the treatment involves before you commit to anything, the Wegovy overview covers the full clinical picture.

What to do next if you want to start (or restart) treatment

If you've been on semaglutide before and treatment was interrupted by supply issues, the clinical position is that resuming needs a prescriber's input, not just a refill. Depending on how long the gap was, a dose reduction and re-titration may be appropriate. That decision belongs to the clinician, based on your history.

If you're considering starting for the first time, the right first step is a consultation with a registered prescriber who can assess whether Wegovy is suitable for you, confirm your eligibility, and check whether the dose schedule that fits your situation is currently available. Information on who can prescribe Wegovy in the UK sets out which healthcare professionals are authorised to do so. At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not a scoring algorithm) on the day you submit it. If treatment is clinically suitable and stock is confirmed, your prescription is dispensed from our own GPhC-registered pharmacy and sent out for free next-working-day delivery. To begin that process, speaking to our prescribers is the place to start.